

This is the 2nd Affidavit  
of Dr. Vince Bain in this case  
and was made on 31/Mar/2016

Court File No. 98-CV-141369 CP00

**ONTARIO**  
**SUPERIOR COURT OF JUSTICE**

B E T W E E N :

DIANNA LOUISE PARSONS, MICHAEL HERBERT CRUICKSHANKS, DAVID TULL,  
MARTIN HENRY GRIFFEN, ANNA KARDISH, ELSIE KOTYK, Executrix of the Estate of Harry  
Kotyk, deceased and ELSIE KOTYK, personally

Plaintiffs

and

THE CANADIAN RED CROSS SOCIETY, HER MAJESTY THE QUEEN IN RIGHT OF ONTARIO  
and  
THE ATTORNEY GENERAL OF CANADA

Defendants

and

HER MAJESTY THE QUEEN IN THE RIGHT OF THE PROVINCE OF ALBERTA  
HER MAJESTY THE QUEEN IN THE RIGHT OF THE PROVINCE OF SASKATCHEWAN,  
HER MAJESTY THE QUEEN IN THE RIGHT OF THE PROVINCE OF MANITOBA,  
HER MAJESTY THE QUEEN IN THE RIGHT OF THE PROVINCE OF NEW BRUNSWICK  
HER MAJESTY THE QUEEN IN THE RIGHT OF THE PROVINCE OF PRINCE EDWARD  
ISLAND,  
HER MAJESTY THE QUEEN IN THE RIGHT OF THE PROVINCE OF NOVA SCOTIA  
HER MAJESTY THE QUEEN IN THE RIGHT OF THE PROVINCE OF NEWFOUNDLAND,  
THE GOVERNMENT OF THE NORTHWEST TERRITORIES,  
THE GOVERNMENT OF NUNAVUT and THE GOVERNMENT OF THE YUKON TERRITORY

Intervenor

*Proceeding under the Class Proceedings Act, 1992*

Court File No. 98-CV-146405

B E T W E E N:

JAMES KREPPNER, BARRY ISAAC, NORMAN LANDRY, as Executor of the Estate of the late  
SERGE LANDRY, PETER FELSING, DONALD MILLIGAN, ALLAN GRUHLKE, JIM LOVE and  
PAULINE FOURNIER as Executrix of the Estate of the late PIERRE FOURNIER

Plaintiffs

and

THE CANADIAN RED CROSS SOCIETY, THE ATTORNEY GENERAL OF CANADA and  
HER MAJESTY THE QUEEN IN RIGHT OF ONTARIO

Defendants

and

HER MAJESTY THE QUEEN IN THE RIGHT OF THE PROVINCE OF ALBERTA,  
HER MAJESTY THE QUEEN IN THE RIGHT OF THE PROVINCE OF SASKATCHEWAN,  
HER MAJESTY THE QUEEN IN THE RIGHT OF THE PROVINCE OF MANITOBA,  
HER MAJESTY THE QUEEN IN THE RIGHT OF THE PROVINCE OF NEW BRUNSWICK,  
HER MAJESTY THE QUEEN IN THE RIGHT OF THE PROVINCE OF PRINCE EDWARD  
ISLAND  
HER MAJESTY THE QUEEN IN THE RIGHT OF THE PROVINCE OF NOVA SCOTIA  
HER MAJESTY THE QUEEN IN THE RIGHT OF THE PROVINCE OF NEWFOUNDLAND,  
THE GOVERNMENT OF THE NORTHWEST TERRITORIES,  
THE GOVERNMENT OF NUNAVUT AND THE GOVERNMENT OF THE YUKON  
TERRITORY

Intervenor

*Proceeding under the Class Proceedings Act, 1992*

No. C965349  
Vancouver Registry

**In the Supreme Court of British Columbia**

Between:

**Anita Endean, as representative plaintiff**

Plaintiff

and:

**The Canadian Red Cross Society  
Her Majesty the Queen in Right of the Province of  
British Columbia, and The Attorney General of Canada**

Defendants

and:

**Prince George Regional Hospital, Dr. William Galliford,  
Dr. Robert Hart Dykes, Dr. Peter Houghton, Dr. John Doe,  
Her Majesty the Queen in Right of Canada, and  
Her Majesty the Queen in Right of the Province of British Columbia**

Third Parties

**Proceeding under the *Class Proceedings Act*, R.S.B.C. 1996, C. 50**

<p>CANADA PROVINCE OF QUÉBEC DISTRICT OF MONTRÉAL</p> <p>NO : 500-06-000016-960</p>	<p>SUPERIOR COURT Class action</p> <hr/> <p>DOMINIQUE HONHON Plaintiff</p> <p>-vs-</p> <p>THE ATTORNEY GENERAL OF CANADA THE ATTORNEY GENERAL OF QUÉBEC THE CANADIAN RED CROSS SOCIETY Defendants</p> <p>-and-</p> <p>MICHEL SAVONITTO, in the capacity of the Joint Committee member for the province of Québec</p> <p>PETITIONER</p> <p>-and-</p> <p>FONDS D'AIDE AUX RECOURS COLLECTIFS -and- LE CURATEUR PUBLIC DU QUÉBEC Mis-en-cause</p>
<p>CANADA PROVINCE OF QUÉBEC DISTRICT OF MONTRÉAL</p> <p>NO : 500-06-000068-987</p>	<p>SUPERIOR COURT Class action</p> <hr/> <p>DAVID PAGE Plaintiff</p> <p>-vs-</p> <p>THE ATTORNEY GENERAL OF CANADA THE ATTORNEY GENERAL OF QUÉBEC THE CANADIAN RED CROSS SOCIETY Defendants</p> <p>-and-</p> <p>FONDS D'AIDE AUX RECOURS COLLECTIFS -and- LE CURATEUR PUBLIC DU QUÉBEC Mis-en-cause</p>

---

**AFFIDAVIT**

---

I, DR. VINCE BAIN, of University of Alberta, 1.55 Zeidler Center, 130 University Campus, Edmonton, Alberta, SWEAR (OR AFFIRM) THAT:

1. My qualifications are as set out in the affidavits I swore in each of these proceedings on March 11, 2015. My updated curriculum vitae is appended as Exhibit A to this affidavit.

2. I have been asked to review the affidavit of Dr. Sam Lee affirmed January 26, 2016 and answer questions about some of the matters on which Dr. Lee opines.

3. In making this affidavit, I certify that I am aware that my duty is to:

- (a) provide opinion evidence that is fair, objective and non-partisan and related only to matters within my area of expertise; and
- (b) assist the court and provide such additional assistance as the court may reasonably require to determine a matter in issue.

4. I am aware that the foregoing duties prevail over any obligation I may owe to any party on whose behalf I am engaged and I am aware that I am not to be an advocate for any party. I confirm that this affidavit conforms with the above-noted duties. I further confirm that if called upon to give oral or written testimony, I will give such testimony in conformity with these duties.

5. At paragraph 21 of his affidavit, Dr. Lee says that "With the introduction of DAA agents in 2011, the treatment burden of HCV-infected persons declined markedly and health outcomes improved greatly...". In my view, an important qualifier to that statement is that the first DAA (direct antiviral agents) drugs introduced in 2011, telaprevir and boceprevir, were associated with a much higher incidence of severe side effects after they were approved than was projected during the trials that preceded their

approval. The side effects included rashes that in some cases became life threatening, nausea, joint pain, anemia, low white blood cell counts, and anal problems such as itching, burning and hemorrhoids. Many more patients than anticipated during the trial phase could not tolerate the full course of therapy and so treatment was discontinued in such patients prior to the prescribed length at the outset. In those with severe side effects, the treatment burden increased and the health outcomes decreased compared to pegylated interferon and ribavirin alone.

6. At paragraph 22 of his affidavit, Dr. Lee refers to DAA drugs approved in 2013 and 2014. Later in that the paragraph he says that current DAA treatment is associated with no discernible side effects and a cure rate exceeding 90%. I put some qualifications on the statement that there are no discernible side effects as follows:

- (a) DAA drugs approved in 2013, simeprevir and sofosbuvir, were combined with pegylated interferon and ribavirin and so those treatment regimes did not avoid the side effects associated with pegylated interferon and ribavirin although the treatment duration was shorter;
- (b) one of the DAA treatment combinations approved in 2014, known commonly as a Holkira Pak (it is a combination of ombitasvir, dasabuvir, paritaprevir and a boosting agent called ritonavir) must be taken with ribavirin for patients with genotypes 1a (which is very common). When combined with ribavirin, the side effects of ribavirin are not avoided and are discernible;
- (c) among the patients I have treated with the 2014 and 2015 drugs which do not include pegylated interferon or ribavirin, (Harvoni and Holkira Pak in some cases), I do not agree that universally there are no discernible side effects. To date, all of my patients have been able to complete the treatment on these regimes, but some do have side effects (described at paragraph 51 of my March 11, 2015 affidavits). The impact of the side effects is markedly less and the side effects do not generally impact day to

day functioning compared to pegylated interferon and ribavirin, telaprevir or boceprevir regimes.

7. The qualifications expressed at paragraphs 6(b) and (c) above apply to the statement of Dr. Lee at paragraph 24 of his affidavit where he says "[t]here is no medical reason to suggest that any patient would undergo a hardship in following either Holkira Pak or Harvoni treatment regimes."

8. At paragraph 31 of his affidavit, Dr. Lee describes that provincial formularies do not cover the cost of Harvoni or Holkira Pak unless the patient has advanced to at least the non-bridging fibrosis of disease stage F2 on the Metavir scale. I agree with this description. I take issue with the following statements in paragraph 31 of Dr. Lee's affidavit:

It may be objected that the only modest benefit of treatment of early-stage HCV infection may be psychological. Treatment offers no useful medical or public health benefits in such patients other than alleviating anxiety from the stress of knowing that they are infected.

9. I take issue with these statements because in my view the eradication of the disease as early as possible in persons who have chronic HCV holds medical benefits for these patients. I note that the current guidelines for treating Hepatitis C issued by the Canadian Association for the Study of the Liver (CASL), and which are attached to my March 11, 2015 affidavits, state that all persons with chronic HCV infection should be considered for treatment. That would include persons below Metavir F2.

10. The medical benefits for the patient include:

(a) some symptoms of HCV chronic infection can occur prior to evidence of liver scarring being detected by biopsy or fibroscan. These symptoms can include fatigue, weight loss, upper right abdominal discomfort, mood disturbance, poor concentration, anxiety and depression. Treating such persons with the chance of also eradicating the symptoms is of medical benefit;

- (b) chronic HCV can be associated with conditions such as cryoglobulinemia, which can cause kidney damage and can occur prior to reaching F2 scarring, and an increased risk of lymphoma, which risk is increased prior to the F2 stage. Avoiding these conditions or treating to eliminate these conditions is of medical benefit;
- (c) conversely, a person can feel well while the process of liver inflammation and scarring proceeds. There is no magical health line crossed at F2, and no way to determine when a person with chronic HCV will cross the line to F2 short of constantly testing the liver through biopsy or fibroscan. In my view, it is medically beneficial to treat a patient with the object of attaining an SVR before the inflammation and/or scarring process has begun or as early as possible in the inflammation and/or scarring process and it is not sound to wait and see if the disease progresses;
- (d) it is understood that chronic HCV is associated with mental health conditions such as mood disturbance, anxiety and depression. These mental health conditions are medical conditions and a corresponding medical benefit of treatment is to avoid or reduce them through treatment.

11. At paragraph 32 of his affidavit, Dr. Lee discusses that financial barriers such as provincial formularies limiting coverage to Metavir F2 and above do not inhibit persons who have access to compensation under the 1986-1990 Hepatitis C Settlement Agreement. He goes on to comment on how physicians would approach treatment in such patients and says "most clinicians would be prepared to accede to the wishes of such a patient so long as he/she understood the financial burden of the antiviral therapy". In my experience it would be approached differently: if the patient has no financial barrier to treatment, for example he or she has private health insurance, access to compensation from the settlement agreement or can afford it personally, then the patient would be counselled to take the treatment. It is not a matter of the patient persuading the clinician, it is a matter of the clinician counselling the patient on the proper course of medical treatment taking into account all of the circumstances.

12. At paragraphs 34-41, Dr. Lee discusses spontaneous viral clearance. With regard to paragraph 34 of Dr. Lee's affidavit, it is not clear to me whether he is suggesting that spontaneous viral clearance can occur in patients after the first year of infection. I consider that to be rare.

13. At paragraph 38 of his affidavit, Dr. Lee states that he expects a spontaneous viral clearance rate among the persons eligible to claim compensation under the 1986-1990 Hepatitis C Settlement Agreement of at least 25%. Dr. Lee's states, at paragraph 42, that most of his patients are not transfused persons eligible to claim under the settlement. The same is true of my practice. My estimate, based on my practice and review of the literature, is that about 1 in 4, or 25%, of persons infected with HCV experience spontaneous viral clearance during or immediately after the acute phase on infection (within 6 months of infection). Spontaneous viral clearance more than year after infection is rare.

14. With regard to paragraphs 43-46 of Dr. Lee's affidavit, my practice includes transfused patients who missed the application deadline for one or the other of the settlements pertaining to persons whose chronic HCV was acquired through blood transfusion or blood product infusion. Those interactions have included persons who were not aware of the settlements prior to the deadline passing.

15. With regard to paragraph 47 of Dr. Lee's affidavit, while I agree that some patients are asymptomatic with chronic HCV, I disagree that patients who are symptomatic "usually have carried the virus for many years and are at or approaching late-stage liver disease". I disagree because some patients are symptomatic at very early stages of chronic HCV infection, as described in paragraph 10(a) above and paragraph 25 of my March 11, 2015 affidavits.


16. With regard to paragraphs 59-62 of Dr. Lee's affidavit, in my view the types of estimates he provides must be qualified as follows:



- (a) the estimates assume that the estimator knows how many people are infected with HCV in total in Canada, and so can determine what percentage of that total are “aware of their need for medical attention” at any given stage. It is not well understood how many people are infected with HCV, and so estimating a percentage of that total based on observing HCV patients in a clinical practice must result in an inherently rough estimate;
  
- (b) as stated above, some persons with chronic HCV have symptoms or develop associated conditions at very early stages of the disease while others are asymptomatic and feel well until late stages of the disease. Given the variability in how HCV infected persons present clinically compared to their actual disease progression, estimates of the sort Dr. Lee provides are not in my view very reliable. At the very least they should be stated as broad ranges because lower or higher estimates could also be reasonable.

17. With regard to paragraphs 59 and 62, in paragraph 59 Dr. Lee states that two-thirds to three-quarters of patients at the cirrhotic stage of HCV infection likely have sought medical attention and been diagnosed. At paragraph 62, Dr. Lee states that 70-85% of persons at level 5, which he describes as compensated cirrhosis, will have presented as patients and have been diagnosed. Since those percentages are different, I assume he means them to cover different groups. The cirrhotic stage can include those with compensated cirrhosis (level 5) and those with decompensated cirrhosis (level 6). The percentage of that group that has presented as patients and been diagnosed should be greater for all cirrhotics (described in paragraph 59) than for compensated cirrhotics alone (level 5 - described in paragraph 62), but Dr. Lee's estimates are the opposite.





November 17, 2015

**BIRTHPLACE:** Edmonton, Alberta, Canada

**CITIZENSHIP:** Canadian

**DOB:** October 12, 1957

**MARITAL STATUS:** Married - Lola T. Baydala (MD, FRCPC - Pediatrics)  
3 Children (Graham, Jessie, Tamara)

**EDUCATION:** 1975 - Senior Matric (Honors) - Strathcona Composite High School, Edmonton.

1979 - B.Sc. with Distinction, University of Alberta, Edmonton, Canada.

1981 - M.D. First-Class Standing with Distinction, University of Alberta, Edmonton, Canada.

**INTERNSHIP:** 1981 - 1982 - Rotating Intern, Victoria Hospital, London, Ontario.

**RESIDENCY:** 1982 - 1985 - Resident in Internal Medicine, University of Alberta Hospital, Edmonton, Alberta.  
Director: Dr. A.M. Edwards.

**FELLOWSHIPS:** 1985 - 1987 - Gastroenterology, University of Alberta Hospital, Edmonton, Alberta. Director: Dr. A.B.R. Thomson.

1987 - 1989 - MRC Research Fellow, Liver Unit, Kings College Hospital, London, England. Supervisor: Dr. Roger Williams.

**CURRENT POSITIONS:** Professor, Div of Gastroenterology, Dept of Medicine, University of Alberta, Edmonton, Canada, 2002 - present.

This is Exhibit "A" referred to in the Affidavit of VINCE BAIN  
Sworn before me this 31 day of MARCH 2016.

*Volandas Van Wachen*  
A Commissioner for Oaths in and for the Province of Alberta  
Volandas Van Wachen

Medical Director, Liver Transplant Program,  
University of Alberta, Edmonton, Canada, 1989-Present.

Director, Liver Unit, Div of Gastroenterology  
Department of Medicine, University of Alberta  
Edmonton, Canada, 2000 - Present

PREVIOUS  
POSITIONS:

Associate Professor, Div of Gastroenterology,  
Dept of Medicine, University of Alberta,  
Edmonton, Canada, 1995 - 2002

Assistant Professor, Division of Gastroenterology,  
Department of Medicine, University of Alberta,  
Edmonton, Canada, 1989 - 1994.

Program Director, GI Fellowship Program,  
University of Alberta, Edmonton, Canada, 1992 - 1997.

NATIONAL  
ADMIN  
POSITIONS:

1998-2000	-Chairman, Education Comm, Cdn Assoc. for the Study of the Liver.
2000-2001	-Vice President, Cdn Assoc. for the Study of the Liver.
2000-2002	-Chairman, Hepatology and Liver Transplant Committee, Cdn Assoc. of Gastroenterology.
2002-2004	-Vice-Chair, Medical Advisory Board, Canadian Liver Foundation
2002-2004	-President, Cdn Assoc for the Study of the Liver.
2004 - 2006	-Chairman, Medical Advisory Board, Canadian Liver Foundation

PROFESSIONAL  
QUALIFICATIONS:

1981	- Licentiate, Medical Council of Canada.
1982	- National Board of Medical Examiners.
1985	- American Board of Internal Medicine.
1986	- Fellow of the Royal College of

		Physicians of Canada - Internal Medicine.
	1987	- Fellow of the Royal College of Physicians of Canada - Gastroenterology.
	1990	- Fellow, American College of Physicians.
LICENCES:	1983- Present	- College of Physicians and Surgeons of Alberta.

#### PROFESSIONAL SOCIETIES AND ORGANIZATIONS:

Alberta Medical Association.

American Association for the Study of Liver Disease.

Canadian Association of Gastroenterology.

Canadian Association for the Study of Liver Diseases.

Canadian Medical Association.

Canadian Transplant Society

European Association for the Study of Liver Diseases.

#### AWARDS

Jonathon B Meddings Clinical Innovation Award 2009-2010

Distinguished Service and Meritorious Achievement Award, Canadian  
Assoc for the Study of the Liver 2012

Excellence in Humanism Certificate, Presented by the Faculty of Medicine  
and Dentistry, 2013.

Awarded Fellowship Designation in the American Association For the Study  
of Liver Diseases, 2014.

Champion of Care recognizing excellence of care by the University of  
Alberta Hospital, 2014.

Prix D'excellence/Specialist of the Year (RAC1). Presented by the Royal  
College of Physicians and Surgeons, 2015.

JOURNAL AND GRANT REVIEWS:  
(last 5 years)

2002 - 2012 - American Journal of Transplantation-Reviewer  
2015- Hepatic Oncology-Reviewer  
2013-2015- Clinical Gastro and Hepatology  
2014 – Liver Transplantation – Reviewer  
2011-2015- Liver International-Reviewer  
2014 – World Journal of Gastro - Reviewer  
1990 - 2012 - Canadian Journal of Gastroenterology. 2000 - 2003,  
Editorial Board  
2009 - 2012 – Transplantation  
2012 – Journal of Viral Hepatitis  
2010 -2014– Hepatology – Reviewer

PUBLICATIONS:

A. Peer Reviewed Articles

1. **Bain GO and Bain VG.**  
Increased numbers of lymphocytes with single class surface immunoglobulins in Hodgkin's Disease.  
American Journal of Clinical Pathology 82:674, 1984.
2. **Bain VG and Bain GO.**  
Lymphocyte populations with abnormal Kappa: Lambda ratios in reactive lymphoid hyperplasia.  
Journal of Surgical Oncology 29:227, 1985.
3. **Bain VG, Ardao GH, Kowalewska-Grochowska K, Wensel RH and Jewell LD.**  
Biliary Ascariasis.  
Journal of Clinical Gastroenterology 10:448, 1988.
4. **Bain VG and Alexander GJM.**  
Progress in the treatment of chronic hepatitis B.  
Journal of Antimicrobial Chemotherapy 22:780, 1988.
5. **Bain VG, Daniels HM, Chanas A, Alexander GJM, Williams R.**  
Foscarnet therapy in chronic hepatitis B virus E antigen carriers.  
Journal of Medical Virology 29:152, 1989.
6. **Bain VG, Bailey RJ, Jhamandas JH.**

Post-shunt myelopathy.  
Journal of Clinical Gastroenterology 13:562, 1991.

7. Lau JYN, Hansen LJ, **Bain VG**, Chaggar K, Smith HM, Portmann BC, Vergani D, Alexander GJM, Williams R.  
Expression of intrahepatic hepatitis D viral antigen in chronic HDV infection.  
Journal of Clinical Pathology 44:549, 1991.
8. Lau JYN, **Bain VG**, Davis SE, Alexander GJM, Williams R.  
Export of intracellular hepatitis B virus (HBV) surface antigen in chronic HBV infection is related to viral replication.  
Hepatology 14:416, 1991.
9. Lau JYN **Bain VG**, Naoumov NV, Smith HM, Alexander GJ Williams R.  
Effect of gamma interferon on hepatitis B viral antigen expression in primary hepatocyte culture.  
Hepatology 14:975,1991.
10. Fingerote RJ, **Bain VG**, Fedorak RN.  
Liver transplants for alcoholic liver disease.  
Canadian Journal of Gastroenterology 5:195,1991.
11. Lau JYN, **Bain VG**, Smith HM, Alexander GJ, Williams R.  
Modulation of hepatitis B viral antigen expression by immunosuppressive drugs in primary hepatocyte culture.  
Transplantation 53:894, 1992.
12. Lau JYN **Bain VG**, Davies SE, O'Grady JG, Alberti A, Alexander GJM, Williams R.  
High level expression of hepatitis B virus antigens in fibrosing cholestatic hepatitis.  
Gastroenterology 102:956,1992.
13. Fingerote RJ, **Bain VG**.  
Fulminant hepatic failure.  
American Journal of Gastroenterology 88:1000, 1993.
14. Mason AL, Wick M, White HM, Benner KH, Lee RG, Regenstein F, **Bain VG**, Campbell C, Perrillo RP.  
Increased hepatocyte expression of hepatitis B virus transcription in patients with features of fibrosing cholestatic hepatitis.  
Gastroenterology 105:237, 1993.
15. Duerksen DR, Jewell LD, **Bain VG**.  
Hepatic giant cell arteritis and polymyalgia rheumatica.  
Canadian Journal of Gastroenterology 8:36, 1994.
16. Ma M, Ryan E, **Bain VG**.

- The development of hemochromatosis after treatment for celiac sprue.  
Canadian Journal of Gastroenterology 8:358, 1994.
17. Tipples GA, Ma MM, Fischer KP, **Bain VG**, Kneteman NM, Tyrrell DL.  
Mutation in HBV RNA-dependant DNA polymerase confers resistance to lamivudine in vivo.  
Hepatology 24:714, 1996.
  18. Shapiro AMJ, **Bain VG**, Sigalet DL, Kneteman NM.  
Rapid resolution of chylous ascites after liver transplantation using somatostatin analog and total.  
Transplantation 61:1410, 1996.
  19. **Bain VG**, Kneteman NM, Ma MM, Gutfreund K, Shapiro AMJ, Fischer KP, Tipples G, Lee H,  
Jewell LD, Tyrrell DL.  
Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and  
decompensated cirrhosis undergoing liver transplantation.  
Transplantation 62:1456,1996.
  20. Duerksen DR, Jewell LD, Mason AL, **Bain VG**.  
Co-existence of hepatitis A and adult Reye=s syndrome.  
GUT 41:121, 1997.
  21. Yoshida EM, Ma MM, Davis JE, Fischer KP, Kneteman NM, Erb SR, Tyrrell LD, **Bain VG**.  
Post-liver transplant allograft re-infection with a lamivudine resistant strain of hepatitis B virus:  
long term follow-up.  
Canadian Journal of Gastroenterology 12:125, 1998.
  22. Kassam N, **Bain VG**.  
Liver transplantation for neuropsychiatric Wilson disease.  
Canadian Journal of Gastroenterology 12:65, 1998.
  23. Poynard T, Marcellin P, Lee S, Niederau C, Minuk G, Ideo G, **Bain VG**, Heathcote J, Zeuzem S,  
Trepo C, Albrecht J.  
An international randomized trial of interferon alfa-2B and ribavirin 48 or 24 weeks vs interferon  
alfa-2B 48 weeks, for first line treatment of chronic hepatitis C.  
Lancet 352:1426, 1998.
  24. Everson GT, Jensen DM, Craig JR, van Leeuwen DJ, **Bain VG**, Ehrinpreis MN, Albert D, John T,  
Witt K, and the Consensus Interferon Study Group.  
Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in  
cirrhotics, fibrotics or nonfibrotics.  
Hepatology 30:271, 1999.
  25. Wong W, **Bain VG**.  
Update in liver transplantation.  
Canadian Family Physician 45:1241, 1999.



26. Pockros PJ, **Bain VG**, Hunter EB, Conrad A, Balart LA, Hollinger FB, Albert D, and the Consensus Interferon Study Group.  
A comparison of RT-PCR and bDNA assays for hepatitis C virus in patients receiving interferon treatment.  
Journal of Viral Hepatitis 6:145, 1999.
27. Shapiro AMJ, **Bain VG**, Preiksaitis JK, Ma MM, Issa S, Kneteman NM.  
Oglovie=s syndrome associated with acute cytomegaloviral infection after liver transplantation.  
Transplant International 13:41,2000.
28. Gutfreund KS, **Bain VG**.  
Chronic viral hepatitis C: Management update.  
Canadian Medical Association Journal 162:827, 2000.
29. **Bain VG**, Abraham N, Jhangri GS, Alexander TW, Henning RC, Hoskinson ME, Maguire CG, Lalor EAG, Sadowski DC.  
Prospective study of biliary strictures to determine the predictors of malignancy.  
Canadian Journal of Gastroenterology 14:397, 2000.
30. Gutfreund KS, Williams M, George R, **Bain VG**, Ma MM, Yoshida EM Villeneuve J-P, Fischer KP, Tyrrell DLJ.  
Genotypic succession of mutations of the hepatitis B virus polymerase associated with lamivudine resistance.  
Journal of Hepatology 33:469, 2000.
31. Romagnuolo J, Jewell DL, Kneteman NM, **Bain VG**.  
Graft-versus-host disease after liver transplantation complicated by systemic aspergillosis with pancarditis.  
Canadian Journal of Gastroenterology 14:637, 2000.
32. **Bain VG**.  
Hepatitis B in transplantation.  
Transplant Infectious Disease 2:153, 2000.
33. **Bain VG**, Montero J-L, de la Mata M.  
Bioartificial liver support.  
Canadian Journal of Gastroenterology 15:313, 2001.
34. Romagnuolo J, Jhangri GS, Jewell LD, **Bain VG**.  
Predicting the liver histology in chronic hepatitis C: How good is the clinician?  
American Journal of Gastroenterology 96:3165, 2001.
35. Wong P, Houston S, Power B, Lalor E, **Bain VG**.  
A case of histoplasma capsulatum causing granulomatous liver disease and Addisonian crisis.

Canadian Journal of Gastroenterology 15:687, 2001.

**36. Bain VG.**

Effect of HCV viral dynamics on treatment design: lessons learned from HIV.  
American Journal of Gastroenterology 96:2818, 2001.

**37. Ramji A, Yoshida EM, Bain VG et al.**

Late Acute Rejection After Liver Transplantation: The Western Canada Experience.  
Liver Transplantation 8:945-951, 2002.

**38. Bain VG, Wong WW, Greig PD and Yoshida EM.**

Hepatology and the Canadian Gastroenterologist: Interest, Attitudes and Patterns of Practice. A National Survey from the Canadian Association of Gastroenterology.  
Canadian Journal of Gastroenterology 17:25-29, 2002.

**39. Abdo AA, Bain VG, Kichian K, Lee SS.**

Evolution of Autoimmune Hepatitis to Primary Sclerosing Cholangitis: A Sequential Syndrome.  
Hepatology 36:1393-1399, 2002.

**40. Kichian K, McLean R, Gramlich LM, Bailey RJ, Bain VG.**

Non-alcoholic Fatty Liver Disease in Patients Investigated for Elevated Liver Enzymes.  
Canadian Journal of Gastroenterology 17:38-42, 2003.

**41. Greig P, Lilly L, Scudamore C, Erb S, Yoshida E, Kneteman N, Bain VG, Ghent C, Marotta P, Grant D, Wall W, Tchervenkov J, Barkun J, Roy A, Marleau D, McAlister V, Peltekian K.**

Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up.  
Liver Transplantation 9:587-595, 2003.

**42. Bain VG.**

Hepatorenal syndrome, hepatopulmonary syndrome, and now, hepatospinal syndrome?  
Liver Transplantation 9:995-996, 2003.

**43. Zeuzem S, Heathcote EJ, Shiffman ML, Wright TL, Bain VG, Sherman M, Feinman SV, Fried MW, Rasenack J, Sarrazin C, Jensen DM, Lin A, Hoffman JH, Sedarati F.**

Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C.  
Journal of Hepatology 39:106-111, 2003.

**44. Dahlan Y, Smith L, Simmonds D, Jewell LD, Wanless I, Heathcote EJ, Bain VG.**

Pediatric-onset primary biliary cirrhosis.  
Gastroenterology 125:1476-1479, 2003.

**45. Bain VG, Bonacini M, Govindarajan S, Ma M, Sherman M, Gibas A, Cotler SJ, Deschenes M, Kaita K, Jhangri GS.**

- A Multicentre study of the usefulness of liver biopsy in hepatitis C.  
Journal of Viral Hepatitis 11:375-382, 2004.
46. Kneteman NM, Oberholzer J, Al Saghler M, Meeberg GA, Blitz M, Ma MM, Wong WW, Gutfreund K, Mason AL, Jewell LD, Shapiro AM, **Bain VG**, Bigam DL.  
Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma.  
Liver Transplantation 10:1301-1311, 2004.
  47. Shin JL, Teitel J, Swain MG, **Bain VG**, Adams PC, Croitoru K, Peltekian K, Schweiger F, Simmons M, Heathcote J.  
A Canadian multicenter retrospective study evaluating transjugular liver biopsy in patients with a congenital bleeding disorders and hepatitis C: is it safe and useful?  
American Journal Hematology. 78:85-93, 2005.
  48. Chatur N, Ramji A, **Bain VG**, Ma MM, Marotta PJ, Ghent CN, Lilly LB, Heathcote EJ, Deschenes M, Lee SS, Steinbrecher UP, Yoshida EM.  
Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian Association for the Study of Liver (CASL) experience with mycophenolate mofetil and tacrolimus.  
Liver International 25:723-27, 2005.
  49. Romangnuolo J, Andrews CN, **Bain VG**, Bonacini M, Cotler SJ, Ma M, Sherman M  
Simple clinical variables predict liver histology in hepatitis C: prospective validation of a clinical prediction model.  
Scandinavian Journal of Gastroenterology 40:1365-71, 2005.
  50. Bistriz L, Tamboli C, Bigam D, **Bain VG**  
Polycystic liver disease: experience at a teaching hospital.  
Am J Gastroenterol. 100:2212-7, 2005.
  51. Mason A, Theal J, Adams E, Perrillo R, **Bain VG**  
Hepatitis B virus replication in damaged endothelial tissues of patients with extrahepatic disease.  
Am J Gastroenterol. 100:972-6, 2005
  52. Yoshida EM, Marotta PJ, Greig PD, Kneteman NM, Marleau D, Cantarovich M, Peltekian KM, Lilly LB, Scudamore CH, **Bain VG**, Wall WJ, Roy A, Balshaw RF, Barkun ST.  
Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial.  
Liver Transpl. 11:1064-72, 2005.
  53. Ghali P, Marotta PJ, Yoshida EM, **Bain VG**, Marleau D, Peltekian K, Metrakos P, Deschenes M.  
Liver transplantation for incidental cholangiocarcinoma: Analysis of the Canadian experience.  
Liver Transpl. 11:1412-6, 2005.

54. Lee SS, **Bain VG**, Peltekian K, Krajden M, Yoshida EM, Deschenes M, Heathcote J, Bailey RJ, Simonyi S, Sherman M.  
Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice.  
*Aliment Pharmacol Ther.* 23:397-408, 2006.
55. **Bain VG**, Kaita KD, Yoshida EM, Swain MG, Heathcote EJ, Neumann AU, Fiscella M, Yu R, Osborn BL, Cronin PW, Freimuth WW, McHutchison JG, Subramanian GM  
A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients.  
*J Hepatol.* 44:671-8, 2006.
56. Mant MJ, **Bain VG**, Maguire CG, Murland K, Yacyshyn BR.  
Prevalence of occult gastrointestinal bleeding in celiac disease.  
*Clinical Gastroenterol Hepatol.* 4:451-4, 2006.
57. Sherman M, Yoshida EM, Deschenes M, Krajden M, **Bain VG**, Peltekian K, Anderson F, Kaita K, Simonyi S, Balshaw R, Lee SS  
Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy.  
*Gut.* 55:1631-8, 2006.
58. **Bain VG**, Yoshida EM, Kaita KD, Swain MG, Heathcote EJ, Garcia A, Moore PA, Yu R, McHutchison JG, Subramanian GM.  
Dynamics of interferon-specific gene expression in peripheral blood of interferon alfa-naive patients with genotype 1 chronic hepatitis C infection treated with albumin-interferon alfa.  
*Hepatol Res.* 35:256-62, 2006.
59. Zeman M, Campbell P, **Bain VG**.  
Hepatitis C eradication and improvement of cryoglobulinemia-associated rash and membranoproliferative glomerulonephritis with interferon and ribavirin after kidney transplantation.  
*Can J Gastroenterol.* 20:427-31, 2006.
60. Bistriz L, **Bain VG**.  
Sphincter of Oddi dysfunction: Managing the patient with chronic biliary pain.  
*World J Gastroenterology,* 12:3793-3802, 2006.
61. Al-Saif F, Al-Masloom A, Johnson MA, **Bain VG**, Sandha GS, Ritchie DB, Shapiro AM.  
Autoimmune pancreatitis with autoimmune hemolytic anemia.  
*Pancreas.* 33:316-7, 2006.
62. McDermid J, Chen M, Li Y, Wasilenko S, Bintner J, McDougall C, Pang X, **Bain VG**, Mason AL.

- Reverse transcriptase activity in patients with primary biliary cirrhosis and other autoimmune liver disorders.  
*Aliment Pharmacol Therapy* 26:587-595, 2007.
63. Toso C, Al-Qahtani M, Alsaif FA, Bigam DL, Meeberg GA, Shapiro AM, **Bain VG**, Kneteman N.  
ABO-incompatible liver transplantation for critically ill adult patients.  
*Transplant International*, 20:675-681, 2007.
64. Tandon P, Rowe BH, Vandermeer B, **Bain VG**.  
The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus.  
*Am J Gastroenterol* 102:1528-1536, 2007.
65. Tandon P, **Bain VG**, Tsuyuki T, Klarenbach S.  
Systematic review: renal and other clinically relevant outcomes in hepatorenal syndrome.  
*Aliment Pharmacol Ther* 25:1017-1028, 2007.
66. Toso C, Meeberg G, Bigam DL, Oberholzer J, Shapiro AMJ, Gutfreund K, Ma, MM, Mason AL, Wong WS, **Bain VG**, Kneteman N.  
De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.  
*Transplantation*, 83:1162-1168, 2007.
67. Chatterjee A, Swain MG, Lee SS, **Bain VG**, Peltekian K, Croitoru K, Adams PC, Kaita K, Teitel J, Heathcote EJ.  
Induction versus noninduction antiviral therapy for chronic hepatitis C virus in patients with congenital coagulation disorders: a Canadian multicentre trial.  
*Can J Gastroenterol*, 21:91-96, 2007.
68. Demeria D, Birchall I, **Bain VG**.  
Dramatic reduction in tumor size in hepatocellular carcinoma patients on thalidomide therapy.  
*Can J Gastroenterol*, 21:517-518, 2007.
69. Powis J, Peltekian KM, Lee SS, Sherman M, **Bain VG**, Cooper C, Krajden M, Deschenes M, Balshaw RF, Heathcote EJ, Yoshida EM.  
Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3.  
*Journal of Viral Hepatitis* (in press).
70. Karvellas C, Gibney N, Kutsogiannis D, Wendon J, **Bain VG**.  
Bench-to-bedside review: current evidence for extracorporeal albumin dialysis systems in liver failure.  
*Critical Care*, 11:215, 2007.
71. Tandon P, Tsuyuki RT, Mitchell L, Hoskinson M, Ma MM, Wong WW, Mason AL, Gutfreund K,

**Bain VG**

- The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study.  
Liver International, 19, 2008
72. Romagnuolo J, Hilsden R, Sandha GS, Cole M, Bass S, May G, Love J, **Bain VG**, McKaigney J, Fedorak RN  
Allopurinol to prevent pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized placebo-controlled trial.  
Clinical Gastroenterology Hepatology, 6:4, 465-71, 2008
73. Zeuzem S, Yoshida EM, Benhamou Y, Pianko S, **Bain VG**, Shouval D, Flisiak R, Rehak V, Grigorescu M, Kaita K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG  
Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C.  
Hepatology, 48:2, 407-17, 2008
74. Alhayaf N, Lalor E, **Bain VG**, McKaigney J, Sandha GS  
The clinical impact and cost implication of endoscopic ultrasound on use of endoscopic retrograde cholangiopancreatography in a Canadian university hospital.  
Canadian Journal of Gastroenterology, 22:2, 138-42, 2008
75. Powis J, Peltekian KM, Lee SS, Sherman M, **Bain VG**, Cooper C, Krajden M, Deschenes M, Balshaw RF, Heathcote EJ, Yoshida EM, Canadian Pegasys Study Group  
Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3.  
Journal of Viral Hepatology, 15:1, 52-7, 2008
76. Kroeker KI, **Bain VG**, Shaw-Stiffel T, Fong TL, Yoshida EM  
Adult liver transplant survey: policies towards eligibility criteria in Canada and the United States 2007.  
Liver International, 28:9, 1250-5, 2008
77. **Bain VG**, Lee SS, Peltekian K, Yoshida EM, Deschênes M, Sherman M, Bailey R, Witt-Sullivan H, Balshaw R, Krajden M, Canadian PEGASYS Study Group  
Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin.  
Aliment Pharmacology Therapy, 29:1, 43-50, 2008
78. **Bain VG**, Kaita KD, Marotta P, Yoshida EM, Swain MG, Bailey RJ, Patel K, Cronin PW, Pulkstenis E, McHutchison JG, Subramanian GM  
Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients.  
Clinical Gastroenterology Hepatology, 6:6, 701-6, 2008

79. Cooper CL, Bailey RJ, **Bain VG**, Anderson F, Yoshida EM, Krajden M, Marotta P, Canadian Pegasys Study Group  
Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians. *Canadian Journal of Gastroenterology*, 22:8, 677-80, 2008
80. Rozenberg L, **Bain VG**, McHutchison JG, Pulkstenis E, Subramanian GM, Neumann AU  
Pharmacodynamics and viral kinetics during albinterferon alfa-2b therapy of chronic hepatitis C genotype 1 treatment-naive patients. *The Journal of Medicine*, 1:1, 2008
81. Montano-Loza AJ, Mason AL, Ma M, Bastiampillai RJ, **Bain VG**, Tandon P  
Risk factors for recurrence of autoimmune hepatitis after liver transplantation. *Liver Transplantation*, 15:10, 1254-61, 2009
82. Montano-Loza AJ, Tandon P, Kneteman N, Bailey R, **Bain VG**  
Rotterdam score predicts early mortality in Budd-Chiari Syndrome, and surgical shunting prolongs transplant-free survival. *Aliment Pharmacol Therapy*, 30:10, 1060-1069, 2009
83. Karvellas CJ, Bagshaw SM, McDermid RC, Stollery DE, **Bain VG**, Gibney RT  
A case-control study of single-pass Albumin dialysis for acetaminophen-induced acute liver failure. *Blood Purification*, 28:3, 151-8, 2009
84. Tandon P, Moncrief K, Madsen K, Arrieta MC, Owen RJ, **Bain VG**, Wong WW, Ma MM  
Effects of probiotic therapy on portal pressure in patients with cirrhosis: a pilot study. *Liver International*, 29:7, 1110-5, 2009
85. Tandon P, Goodman KJ, Ma MM, Wong WW, Mason AL, Meeberg G, Bergsten D, Carbonneau M, **Bain VG**  
A shorter duration of pre-transplant abstinence predicts problem drinking after liver transplantation. *Am J Gastroenterology*, 104:7, 1700-6, 2009
86. Yoshida EM, Sherman M, **Bain VG**, Cooper CL, Deschênes M, Marotta PJ, Lee SS, Krajden M, Witt-Sullivan H, Bailey R, Usaty C, Peltekian K, Pegasys Study Group  
Re-treatment with Peginterferon alfa-2a and Ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of Pegylated Interferon-based therapy. *Canadian Journal of Gastroenterology*, 23:3, 180-4, 2009
87. Fouad TR, Abdel-Razek WM, Burak KW, **Bain VG**, Lee SS  
Prediction of cardiac complications after liver transplantation. *Transplantation*, 87:5, 763-70, 2009
88. Neumann AU, **Bain VG**, Yoshida EM, Patel K, Pulkstenis E, Subramanian GM  
Early prediction of sustained virological response at day 3 of treatment with Albinterferon-Alpha-2b in patients with genotype 2/3 chronic hepatitis C.

Liver International, 29:9, 1350-5, 2009

89. Carbonneau M, Jensen LA, **Bain VG**, Kelly K, Meeberg G, Tandon P  
Alcohol use while on the liver transplant waiting list – a single center experience.  
Liver Transplantation, 16:91-97, 2010
90. Asthana S, Maguire C, Lou L, Meier M, **Bain V**, Townsend R, Lien D, Bigam D, Kneteman N, Shapiro A.  
Successful resolution of severe hepatopulmonary syndrome following liver transplantation.  
Transplant International, 23:432-435, 2010
91. Moncreif KJ, Savu A, Ma MM, **Bain VG**, Wong WW, Tandon P.  
The natural history of inflammatory bowel disease and primary sclerosing cholangitis after liver transplantation – a single centre experience.  
Canadian Journal Gastroenterology, 24:1, 40-6, 2010
92. Emamaullee JA, Edgar R, Toso C, Thiesen A, **Bain V**, Bigam D, Kneteman N, Shapiro AM.  
Vascular endothelial growth factor expression in hepatic epithelioid hemangioendothelioma: Implications for treatment and surgical management.  
Liver Transplantation, 16:191-197, 2010
93. Deschenes M, **Bain VG**, Lee SS, Sherman M, Cooper CL, Yoshida EM, Marotta PJ, Krajden M, Usaty C, Balshaw R, Peltekian KM, Canadian Pegasys Study Group.  
Identifying HCV genotype 1 patients at risk of relapse.  
European Journal Gastroenterology Hepatology, 22:5, 546-51, 2010
94. Meza-Junco J, Montano-Loza AJ, Ma M, Wong W, Sawyer MB, **Bain VG**.  
Cholangiocarcinoma: has there been any progress?  
Canadian Journal Gastroenterology, 24:1, 52-7, 2010
95. Nelson DR, Benhamou Y, Chuang WL, Lawitz EJ, Rodriguez-Torres M, Flisiak R, Rasenack JW, Kryczka W, Lee CM, **Bain VG**, Pianko S, Patel K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG, ACHIEVE-2/3 Study Team.  
Albinterferon Alfa-2b was not inferior to pegylated interferon-? in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3.  
Gastroenterology, 139:4, 1267-76, 2010
96. Jayakumar S, **Bain V**.  
Rational Guide to the Use of Erythropoietin in the Treatment of HCV Infection.  
Current Hepatitis Reports 10:62-69, 2011
97. Peltekian KM, **Bain VG**, Lee SS, Sherman M, Cooper CL, Yoshida EM, Marotta PJ, Krajden M, Balshaw R, Deschênes M.  
Is pre-treatment liver biopsy necessary for all hepatitis C genotypes?  
Annals Hepatology 10:260-9, 2011



98. Chopra A, Cantarovich M, **Bain VG**.  
Simultaneous liver and kidney transplants: optimizing use of this double resource.  
*Transplantation* 91:1305-9, 2011
99. Montano-Loza AJ, Meza-Junco J, Prado CM, Lieffers JR, Baracos VE, **Bain VG**, Sawyer MB.  
Muscle Wasting Is Associated With Mortality in Patients With Cirrhosis.  
*Clinical Gastroenterology and Hepatology* 10:166-73, 2012
100. Meza-Junco J, Montano-Loza AJ, Liu DM, Sawyer MB, **Bain VG**, Ma M, Owen R.  
Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?  
*Cancer Treat Review* 38:54-62, 2012
101. Montano-Loza AJ, Vargas-Vorackova F, Ma M, **Bain VG**, Burak K, Kumar T, Mason AL.  
Incidence and risk factors associated with de novo autoimmune hepatitis after liver transplantation.  
*Liver International* 32(9): 1426-33, 2012
102. Ye C, Saincher M, Tandon P, Meeburg G, Williams R, Burak KW, **Bain VG**.  
Cardiac work-up protocol for liver transplant candidates: experience from a single liver transplant centre.  
*Canadian Journal of Gastroenterology* 26(11) :806-810, 2012
103. Tandon P, Ney M, Irwin I, Ma MM, Gramlich L, **Bain VG**, Esfandiari N, Baracos V, Montano-Loza AJ, Myers RP.  
Severe muscle depletion in patients on the liver transplant wait list : its prevalence and independent prognosis value.  
*Liver Transplantation* 18(10) : 1209-16, 2012
104. Lambert JE, **Bain VG**, Ryan EA, Thomson AB, Clandinin MT.  
Elevated lipogenesis and diminished cholesterol synthesis in patients with hepatitis C viral infection compared to healthy humans.  
*Hepatology* 57(5) :1697-1704, 2013
105. Alameel T, **Bain VG**, Sandha G.  
Clinical application of a single-operator direct visualization system improves the diagnostic and therapeutic yield of endoscopic retrograde cholangiopancreatography.  
*Canadian Journal of Gastroenterology* 27(1):15-9, 2013.
106. Kao D, Zepeda-Gomez S, Tandon P, **Bain VG**.  
Managing the post-liver transplantation anastomotic biliary stricture: multiple plastic versus metal stents: a systematic review.  
*Gastrointestinal Endoscopy* 77(5):679-91, 2013.

107. Al-Judaibi B, **Bain VG**, Sis B.  
An unusual cause of elevated liver enzymes in a diabetic patient.  
*Gastroenterology* 144(7):1354, 1577-8, 2013.
108. Meza-Junco J, Montano-Loza AJ, Baracos VE, Prado CM, **Bain VG**, Beaumont C, Esfandiari N, Lieffers JR, Sawyer MB.  
Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma  
*Journal of Clinical Gastroenterology* 47(10): 861-870, 2013
109. Jayakumar S, Carbonneau M, Hotte N, Befus AD, St Laurent C, Owen R, McCarthy M, Madsen K, Bailey RJ, Ma M, **Bain V**, Rioux K, Tandon P  
VSL#3 probiotic therapy does not reduce portal pressures in patients with decompensated cirrhosis  
*Liver International* 33(10):1470-7, 2013
110. Wells MM. Roth LS. Marotta P. Levstik M. Mason AL. **Bain VG**. Chandok N. Aljudaibi BM.  
Increased duration of dual pegylated interferon and ribavirin therapy for genotype 1 hepatitis C post-liver transplantation increases sustained virologic response: a retrospective review  
*Saudi Journal of Gastroenterology*. 19(5):223-9, 2013.
111. Bhanji RA, Ma M, **Bain VG**, Montano-Loza AJ.  
Hyperhomocysteinemia is associated with severity of cirrhosis and negative impact after liver transplantation.  
*Liver International*, 2015. Oct 16. doi: 10.1111/liv.12979. [Epub ahead of print]
112. Kao D, Roach B, Park H, Hotte N, Madsen K, **Bain V**, Tandon P.  
Fecal microbiota transplantation in the management of hepatic encephalopathy.  
*Hepatology*, 2015 doi:10.1002/hep.28121
113. Burak KW, Meeberg GA, Myers RP, Fick GH, Swain MG, **Bain VG**, Kneteman NM, Hilsden RJ.  
Validation, current use and future directions of the Model for End-stage Liver Disease for liver transplant allocation in Canada.  
*Canadian Journal of Gastroenterology and Hepatology*, 2015 Jun 15. pii: 16942. [Epub ahead of print] .
114. Tandon P, Abraldes J, Keough A, Bastiampillai R, Jayakumar S, Carbonneau M, Wong E, Kao D, **Bain VG**, Ma M.  
Risk of Bacterial Infection in Patients with Cirrhosis and Acute Variceal Hemorrhage, Based on Child-Pugh Class, and Effects of Antibiotics.  
*Clinical Gastroenterology and Hepatology*, 13(6):1189-1196, 2015.

## B. Book Chapters and Invited Contributions

1. **Bain VG** and Thomson ABR.  
The safety and effectiveness of misoprostol in the treatment of duodenal ulcer.  
Internal Medicine for the Specialist 8:73, 1987.
2. **Bain VG** and Thomson ABR.  
Update in Small Bowel Disease.  
In: Current Gastroenterology Vol 8, Editor G. Gitnick, 1988.
3. **Bain VG** and Thomson ABR.  
Gastrointestinal and hepatic complications in the intensive care unit.  
Medicine North America 18:3524, 1988.
4. **Bain VG**, Alexander GJM, Eddleston ALWF.  
Viral Hepatitis.  
In: Immunology and Immunopathology of the Liver and Gastrointestinal Tract.  
Eds. Targan S.R. and Shanahan F. 1990.
5. **Bain VG**, Minuk GY.  
Jaundice, ascites and hepatic encephalopathy. In:  
Oxford Textbook of Palliative Care, Oxford University Press 1993.
6. **Bain VG** (Ed), Depew W, Steinbrecher U.  
Hepatitis Update. Would you treat this patient? A debate regarding controversial aspects of  
chronic hepatitis C and its management.  
Canadian Journal of Gastroenterology 10:81, 1996.
7. **Bain VG**.  
Hepatitis Update. Literature Review - Hepatitis C current findings - What=s new?  
Canadian Journal of Gastroenterology 11:141, 1997.
8. **Bain VG**.  
Jaundice, ascites and hepatic encephalopathy.  
In: Oxford Textbook of Palliative Medicine,  
Oxford University Press, 1997.
9. **Bain VG**, Ma M.  
Acute Viral Hepatitis.  
In: First Principles of Gastroenterology, Third Ed. Eds, Thomson ABR, Shaffer E, 1997.
10. **Bain VG**, Ma M.  
Chronic Hepatitis.  
In: First Principles of Gastroenterology, Third Ed. Eds, Thomson ABR, Shaffer E, 1997.
11. **Bain VG**.

Hepatitis C - What does the future hold? (Editorial)  
Canadian Journal of Gastroenterology 14:571, 2000.

12. **Bain VG** and Ma M.  
Acute Viral Hepatitis  
In: First Principles of Gastroenterology, Fourth Ed. Eds. Thomson ABR, Shaffer E, 2000.
13. **Bain VG** and Ma M.  
Chronic Hepatitis  
In: First Principles of Gastroenterology, Fourth, Ed. Eds. Thomson ABR, Shaffer E, 2000.
14. Lam E and **Bain VG**.  
Hepatitis as a World Health Problem.  
Encyclopaedia of Life Sciences, Nature Publishing Group, 2001 ([www.els.net](http://www.els.net)).
15. Kichian K and **Bain VG**.  
Jaundice, ascites and hepatic encephalopathy.  
In: Oxford Textbook of Palliative Medicine Oxford University Press 2003.
16. Grover P, **Bain VG**.  
Chronic hepatitis.  
In: First Principles of Gastroenterology, Fifth Ed. Eds. Thomson ABR, Shaffer E, 2005.
17. **Bain VG**.  
Exciting experimental therapies in acute liver failure.  
Gastroenterology Canada, Vol 7(3), 2005.
18. **Bain VG**, Tandon P.  
Hepatitis as a World Health Problem.  
In: Encyclopedia of Life Sciences, Nature Publishing Group, 2006 ([www.els.net](http://www.els.net)).
19. **Bain VG**, Tandon P.  
Hepatitis as a World Health Problem.  
Encyclopedia of Life Sciences, John Wiley & Sons, Ltd: Chichester  
[http://www.els.net/\[doi:10.1002/9780470015902.a0002236.pub2\]](http://www.els.net/[doi:10.1002/9780470015902.a0002236.pub2]), 2007.

C. Group Publications

1. **Canadian Association for the Study of the Liver: Hepatitis Consensus Group**.  
Treatment of Chronic Viral Hepatitis with Alpha-Interferon: A Consensus Conference Report.  
Canadian Journal Gastroenterology 8:179, 1994 and Canadian Journal of Infectious Diseases  
5:107, 1994.
2. **The North American Crohn's Study Group Investigators**.

Methotrexate for the treatment of Crohn's disease.  
New England Journal of Medicine 332:292, 1995.

3. **Canadian Association for the Study of the Liver Hepatitis Consensus Group.**  
Management of viral hepatitis: clinical and public health perspectives - A consensus statement.  
Canadian Journal of Gastroenterology 11:407, 1997.
4. Keefe EB, Hollinger FB and **The Consensus Interferon Study Group.**  
Therapy of hepatitis C: Consensus interferon trials.  
Hepatology 26 (Suppl.)101S, 1997.
5. Tong MJ and **the Consensus Interferon Study Group.**  
Treatment of chronic hepatitis C with consensus interferon: A multicentre randomized controlled trial.  
Hepatology 26:747, 1997.
6. Heathcote JE, Keefe EB, Lee SS and **the Consensus Interferon Study Group**  
Re-treatment of chronic hepatitis C with consensus interferon.  
Hepatology 27:1136, 1998.
7. Grant D, Kneteman N, Roy A and **the Canadian Liver Transplant Study Group.**  
Peak cyclosporin levels correlate with freedom from liver graft rejection: results of a prospective randomized comparison of neoral and sandimmune for liver transplantation.  
Transplantation 67:1133, 1999.
8. Keefe EB, Dusheiko GM, Tong MJ and **the Consensus Interferon Study Group.**  
Genotype does not affect pattern of HCV RNA decrease among responders during interferon treatment of chronic hepatitis.  
Cytokines, Cellular & Molecular Therapy 5:211, 1999.
9. Keefe EB, Dusheiko GM, James SP and **the Consensus Interferon Study Group.**  
Utility of hepatitis C virus serotypes in predicting response to treatment of chronic hepatitis C.  
Cytokines, Cellular & Molecular Therapy 5:207, 1999.
10. Grant D, Kneteman N, Tchervenkov J, Roy A, Murphy G, Tan A, Hendricks L, Giulbault N, Levy G.  
Peak cyclosporine levels (C max) correlate with freedom from liver graft rejection.  
Transplantation 67:1133-1999.
11. Heathcote JE, James S, Mullen KD, Hauser SC, Rosenblate H, Albert Jr DG and **the Consensus Interferon Study Group.**  
Chronic hepatitis C virus patients with breakthroughs during interferon treatment can successfully be retreated with consensus Interferon.  
Hepatology 30: 562-1999.

12. Wong F, Blei AT, Blendis LM, Thuluvath PJ, for **The North American VPA-985 Study Group**.  
A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized placebo-controlled trial. *Hepatology* 37:182-190, 2003.
13. Sherman M, **Bain VG**, Villeneuve J-P, Myers RP, Cooper C, Martin S, Lowe C. The management of chronic viral hepatitis: A Canadian Consensus Conference, [www.hepatology.ca](http://www.hepatology.ca), 2004, and *Canadian Journal of Gastroenterology* 18:715-728, 2004
14. Angeli P, Wong F, Watson H, Gines P and the CAPPS Investigators. Hyponatremia in cirrhosis: results of a patient population survey. *Hepatology*, 44:1535-1542, 2006.

**D. Abstracts & Brief Communications (1-100 Thinned – available on request)**

101. Chatur N, Ramji A, **Bain VG**, Ma M, Marotta P, Ghent C, Lilly L, Heathcote EJ, Deschenes M, Steinbrecher U, Yoshida E.  
Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: The CASL experience with mycophenolate mofetil and Tacrolimus, *American Gastroenterology Association*, Feb; M1982, 2004.  
*Canadian Journal of Gastroenterology*. Sep;18:(Suppl A):94A, 2004.
102. Kichian K, Gerhardt A, Gutfreund K, Jewell L, Ma M, Mason AL, Mulesa L, Wong W, **Bain VG**.  
The role of the glucose challenge test in the evaluation of patients with non-alcoholic fatty liver disease.  
*Canadian Journal of Gastroenterology*, 18:93A (Suppl A), 2004.
103. Bistriz L, Tamboli C, **Bain VG**.  
Polycystic liver disease: Experience at a teaching hospital.  
*Canadian Journal of Gastroenterology*, 18: 93A (Suppl A), 2004.
104. Teitel J, Heathcote EJ, Shin J, Swain MG, **Bain VG**, Adams PC, Croitoru K, Peltekian K, Schweiger F, and Simons ME.  
A Canadian multicenter study evaluating transjugular liver biopsy in patients with hepatitis C and congenital bleeding disorders.  
*Haemophilia*. March 10: 46-50 (Suppl 3), 2004.
105. Shin J, Teitel J, Swain M, **Bain VG**, Peltekian K, Croitoru K, Adams P, Simons M, Heathcote EJ.  
Risks and benefits of transjugular liver biopsy in patients with congenital coagulation disorders.  
*Can J Gastroenterol*. Feb;18: 87A (Suppl A), 2004.
106. Kichian K, Gerhardt A, Gutfreund K, Jewell L, Ma M, Mason A, Mulesa L, Wong W, **Bain VG**.  
The role of the glucose challenge test in the workup of patients with non alcoholic fatty liver disease.

- American Gastroenterology Association, T1100, 2004,  
Can J Gastroenterol. Feb;18: 93A (Suppl A), 2004.
107. Mathew G, Meeberg G, **Bain VG**, Lalor E, McKaigney J, Kneteman N, Sandha G.  
Endoscopic therapy of biliary strictures after orthotopic liver transplantation.  
Can J Gastroenterol. 18:(Suppl A):85A, 2004.
108. Feinman SV, **Bain VG**, Peltekian K, Marotta P, Deschenes M.  
Efficacy and safety of peginterferon alfa-2a in combination with ribavirin in Canadian patients with chronic hepatitis C: Interim results in cirrhotic and non-cirrhotic patients.  
Can J Gastroenterol. Feb;18:(Suppl A):84A, 2004
109. **Bain VG**.  
Clinical trials registry (letter).  
Canadian Medical Association Journal 172:979-80, 2005
110. Rozenberg L, **Bain VG**, Neumann AU.  
HCV kinetics as function of albuferon pharmacodynamics in subjects with genotype 1 chronic hepatitis C.  
12<sup>th</sup> International Symposium on HCV and Related Viruses, Montreal, Oct 2-6, 2005, Hepatology 2005.
111. **Bain VG**, Kaita K, Yoshida E, Swain M, Heathcote J, McHutchison J, Neumann A, Bagchi P, Osborn B, Cronin P, Novello L, Freimuth W, Subramanian M.  
A phase 2 study to assess antiviral response, safety, and pharmacokinetics of albuferon in IFN-alpha naïve subjects with genotype 1 hepatitis C.  
40<sup>th</sup> Annual Meeting of EASL, Paris, France, Apr 13-17, 2005, Journal of Hepatology 42:(Supplement):9, 2005.
112. Sherman M, Yoshida E, Deschenes M, Krajden M, **Bain VG**, Peltekian K, Anderson F, Kaita K, Simonyi S, Lee S.  
Peginterferon alpha-2a (40 kDa) plus ribavirin in chronic hepatitis C patients who failed previous interferon-based therapy: results of a multicenter open-label expanded access program in Canada.  
40<sup>th</sup> Annual Meeting of EASL, Paris, France, Apr 13-17, 2005, Journal of Hepatology. 42:(Supplement):220, 2005.
113. Lee S, **Bain VG**, Peltekian K, Krajden M, Yoshida E, Deschenes M, Heathcote EJ, Bailey R, Simonyi S, Sherman M.  
Peginterferon alpha-2a (40 kDa) plus ribavirin in cirrhotic patients with chronic hepatitis C: results of a Canadian Multicentre open-label expanded access program. 2005, Journal of Hepatology 42:(Supplement):209, 2005.
114. Johnson M, **Bain VG**, Bigam D, Gutfreund K, Kneteman N, Mason A, Meeberg G, Shapiro J, Wong W, Ma M.  
Liver transplantation for hepatocellular carcinoma: the significance of microvascular invasion and

factors associated with cancer recurrence post-liver transplant.  
World Congress of Gastroenterology, Sept 10-14, Montreal, QC, 2005.

115. Yoshida E, Heathcote J, Bailey R, Anderson F, Kaita K, Krajden M, Deschenes M, **Bain VG**, Lee S, Sherman M, Peltekian K, Simoni S.  
“Real World”: experience with peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C: results of a multicenter open-label expanded access program in Canada.  
Gastroenterology 128(4, Suppl 2):A723, 2005.
116. Grover PT, Kneteman N, Shapiro J, Bigam D, Ma M, Mason A, Wong W, **Bain VG**, Gutfreund K.  
Rapid intrahepatic recurrence of hepatic mangioendothelioma after living donor liver transplantation.  
CASL, March, Banff, 2005.
117. Peltekian K, Deschenes M, Lee S, **Bain V**, The Canadian Pegasys Study Group.  
Predictability of early virological response to peginterferon alfa-2A (40KD) plus ribavirin in the “Real World”.  
CASL, March, Banff, 2005.
118. **Bain V**, Kaita K, Yoshida E, Swain M, Heathcote J, McHutchinson J, Garcia A, Bagchi P, Cronin P, Novello L, Freimuth W, Moor P, Subramanian M.  
Interferon specific gene expression mediated by albuferon in IFNA naïve subjects and correlation with anti-viral response.  
CASL, March, Banff, 2005.
119. Peltekian K, Deschenes M, Lee S, **Bain V**, The Canadian Pegasys Study Group.  
Predictability of early virological response to peginterferon alfa-2A (40KD) plus ribavirin in the “Real World”.  
Gastroenterology 128:(4, Suppl 2):A-721, 2005.
120. Burak K, Meeberg G, Myers R, Hilsden R, Swain M, Wong W, Fick G, **Bain VG**.  
Should Canada adopt the MELD score for allocation of liver transplants?  
Can J Gastroenterol 20:194, 2006.
121. Cooper C, Bailey R, **Bain VG**, Anderson F, Marotta P.  
Canada’s first nations with chronic hepatitis C: therapeutic outcomes of the pegasys expanded access program.  
Can J Gastroenterol 20:197, 2006.
122. Powis J, Peltekian K, Lee S, Sherman M, **Bain VG**, Cooper C, Krajden M, Balshaw R, Heathcote J, Yoshida.  
Is it time to separate the management of genotype 2 and genotype 3 in chronic hepatitis C?  
Can J Gastroenterol 20:207, 2006.
123. **Bain VG**, Lee SS, Peltekian K, Yoshida E, Deschênes M, Sherman M, Bailey R, Witt-Sullivan H,



- Balshaw R, Krajden M.  
Exposure to ribavirin (RBV) predicts EVR and SVR in patients with HCV genotype 1 infection: analysis of the Canadian pegasys expanded access program (EAP).  
Hepatology 44:335A, 2006.
124. McHutchison J, Zeuzem S, Benhamou Y, Shouval D, **Bain VG**, Pianko S et al.  
Interim antiviral and safety data with albumin interferon alfa-2B combined with ribavirin in a phase 2B study conducted in a genotype 1, IFN-naïve, chronic hepatitis C population.  
Hepatology 44:614A, 2006.
125. Grover PT, Rowe BH, Vandermeer B, **Bain VG**.  
The efficacy and safety of bile acid binding agents, opioid antagonists or rifampin in the treatment of cholestasis associated pruritus.  
Hepatology 44:636A, 2006.
126. Nudo C, **Bain VG**, Marleau D, Marotta P, Wong P, Yoshida E et al.  
Liver transplantation for hepatic epithelioid hemangioendothelioma and neuroendocrine tumors: the Canadian multicenter experience.  
Hepatology 44:411A, 2006.
127. Fiscella M, Balan V, Nelson D, **Bain VG**, Zeuzem S, McHutchison J et al.  
Favorable pharmacokinetics of albumin interferon alfa in subjects with chronic hepatitis C.  
Hepatology 44:613A, 2006.
128. Zeuzem S, Benhamou Y, **Bain VG**, Shouval D, Pianko S, Flisiak R, Grigorescu M, Rehak V, Yoshida E, Kaia K, Cronin P, Pulkstenis E, Subramanian M, McHutchison J.  
Antiviral response at week 12 following completion of treatment with albinterferon  $\alpha$ 2b plus ribavirin in genotype 1, IFN-naïve, chronic hepatitis C patients.  
J Hepatol 46(Suppl 1):S293, 2007.
129. Deschênes M, Yoshida E, Peltekian K, Cooper C, **Bain VG**, Krajden M, Sherman M, Lee SS, Balshaw R, Marotta P.  
Management of chronic hepatitis C in a diverse population with peginterferon  $\alpha$ -2a and ribavirin: final results of the Canadian pegasys expanded access program (EAP).  
J Hepatol 46(Suppl 1):S232, 2007.
130. **Bain VG**, Marotta P, Kaita K, Yoshida E, Swain M, Bailey R, Neumann A, Cronin P, McHutchison J, Pulkstenis E, Subramanian M.  
Comparable antiviral response rates with albumin interferon alfa-2b dosed at Q2W or Q4W intervals in naïve subjects with genotype 2 or 3 chronic hepatitis C.  
J Hepatol 46(Suppl 1):S7, 2007.
131. **Bain VG**, Lee SS, Peltekian K, Yoshida E, Deschênes M, Sherman M, Bailey R, Witt-Sullivan H, Balshaw R, Krajden M.  
Exposure to ribavirin (RBV) predicts EVR and SVR in patients with HCV genotype 1 infection:

- analysis of the Canadian pegasys expanded access program (EAP).  
Can J Gastroenterol, 21(Suppl A):155A, 2007.
132. Zeman M, Meeberg G, Belland D, **Bain VG**, Bigam D, Grover P, Gutfreund K, Kneteman N, Mason A, Shapiro J, Wong W, Ma M.  
The impact of nutritional status on prediction of outcome in patients awaiting and following liver transplantation.  
Can J Gastroenterol 21(Suppl A):146A, 2007.
133. Deschênes M, Lee SS, Cooper C, Marotta P, **Bain VG**, Sherman M, Scully L, Wong D, Balshaw R, Peltekian K.  
Is it possible to identify HCV genotype 1 patients at risk of relapse? Analysis of the Canadian Pegasys expanded access program (EAP).  
Can J Gastroenterol 21(Suppl A):78A, 2007.
134. Pianko S, Yoshida EM, Zeuzem S, Benhamou Y, **Bain VG**, Pulkstenis E, McHutchison JG, Subramanian GM.  
Favorable quality of life (QOL) with albinterferon alfa-2b plus ribavirin in genotype 1, IFN-naïve, chronic hepatitis C (CHC) patients.  
Hepatology, 46(Suppl 1):822A, 2007.
135. Zeuzem S, Yoshida EM, Benhamou Y, **Bain VG**, Shouval D, Pianko S, Flisiak R, Grigorescu M, Rehak V, Kaita KD, Cronin P, Pulkstenis E, Subramanian GM, McHutchison JG.  
Sustained virologic response rates with albinterferon alfa-2B plus ribavirin treatment in IFN-naïve, chronic hepatitis C genotype 1 patients.  
Hepatology, 46(Suppl 1):317A, 2007.
136. Romagnuolo J, Hilsden R, Sandha GS, Cole M, Bass S, May G, Love J, **Bain VG**, McKaigney J, Fedorak RN  
Allopurinol to prevent pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized placebo-controlled trial.  
Clinical Gastroenterology Hepatology, 6:4, 465-71, 2008
137. Stephen Pianko, Eric M. Yoshida, Stefan Zeuzem, Yves Benhamou, **Vincent G. Bain**, et al  
Health-Related Quality of Life (HRQOL) with Albinterferon Alfa-2b Plus Ribavirin in IFN Treatment-Naïve Patients with Genotype 1 Chronic Hepatitis C.  
Gastroenterology, 134:4, 787A, 2008
138. Adivan U. Neumann, Lynn Rozenberg, **Vincent G. Bain**, John G. McHutchison, et al  
Viral Kinetics and Pharmacodynamics of Albinterferon Alfa-2b in Interferon Treatment-Naïve Patients with Genotype 1, Chronic Hepatitis C.  
Gastroenterology, 134:4, 788A, 2008
139. Puneeta Tandon, Karen J. Goodman, Mang M. Ma, Winnie Wong, Andrew L. Mason, Glenda Meeberg, Donna Bergsten, Michelle Carbonneau, **Vincent G. Bain**

- The Duration of Pre-Transplant Abstinence is an Independent Predictor of Problem Drinking Post Liver Transplantation  
Hepatology, 48:4, 555A-556A, 2008
140. Aldo J. Montano-Loza, Andrew L. Mason, Mang M. Ma, **Vincent G. Bain**, et al  
Risk Factors for Recurrence of Autoimmune Hepatitis After Liver Transplantation  
Hepatology, 48:4, 1091A-1092A, 2008
141. P Tandon, KJ Goodman, G Meeburg, D Bergstrom, C Hoekstra, M Carbonneau, **VG Bain**  
The Duration of Pre-Transplant Abstinence is an Independent Predictor of Problem Drinking Post Liver Transplantation  
Gastroenterology, 22, 132A, 2008
142. KI Kroeker, **VG Bain**, T Shaw-Stiffel, T. Fong, et al  
Adult Liver Transplant Survey: Policies Towards Eligibility Criteria in Canada and the United States in 2007  
Gastroenterology, 22, 125A, 2008
143. P. Tandon, RT Tsuyuki, L. Mitchell, M. Hoskinson, MM Ma, WW Wong, AL Mason, K Gutfreund, **VG Bain**  
The Effect of Midodrine, Octreotide and Albumin in Refractory Ascites  
Gastroenterology, 22, 120A, 2008
144. J Romagnuolo, R Hilsden, GS Sandha, M Cole, S Bass, G May, J Love, **VG Bain**, J McKaigney, RN Fedorak  
Allopurinol to prevent pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP): Final Results from a randomized multi-centered placebo-controlled trial  
Gastroenterology, 22, 79A, 2008
145. TR Fouad, AAM Shaheen, KW Burak, **VG Bain**, et al  
Prediction of Cardiac Complications After Liver Transplantation  
Gastroenterology, 22, 81A, 2008
146. K. Moncrief, A. Savu, MM Ma, **VG Bain**, P. Tandon  
The Course of Inflammatory Bowel Disease (IBD) and Primary Sclerosing Cholangitis (PSC) After Liver Transplantation for PSC  
Gastroenterology, 22, 90A, 2008
147. Y. Benhamou, S. Zeuzem, E. Yoshida, **V. Bain**, et al  
Sustained Virologic Response with Albuinterferon Alfa-2b Plus Ribavirin Treatment in IFN-Naïve, Chronic Hepatitis C Genotype 1 Patients  
Hepatology International, 2, A167, 2008
148. **V. Bain**, K. Kaita, P. Marotta, E. Yoshida, M. Swain, R. Bailey, K. Patel, P. Cronin, E. Pulkstenis, J. Mchutchison, M. Subramanian

- Albinterferon Alfa-2b Dosed at 4-Week Intervals Demonstrates Clinically Meaningful Antiviral Activity in Chronic Genotype 2 or 3 Hepatitis C Virus Infection: Results of a Phase 2 Study  
*Hepatology International*, 2, A168, 2008
149. Kroeker KI, **Bain VG**, Shaw-Stiffel T, Fong TL, Yoshida EM  
Adult liver transplant survey: policies towards eligibility criteria in Canada and the United States  
2007  
*Liver International*, 28:9, 1250-55, 2008
150. Nelson D, Benhamou Y, Chuang WL, Lawitz E, Flisiak R, Rodriguez-Torres M, **Bain VG**, Patel K, Cronin PW, Pulkstenis E, Subramanian GM, McHutchison JG  
Efficacy and safety results of albinterferon alfa-2B in combination with ribavirin in interferon-alfa treatment naïve patients with genotype 2 or 3 chronic hepatitis C  
*Journal of Hepatology*, 50:1, S378, 2009
151. Sulkowski MS, Zeuzem S, Lawitz E, Grigorescu M, Tice AD, Rustgi VK, Rodriguez-Torres M, Lurie Y, Cianciara J, Bacon BR, **Bain VG**, Kryczka W, Pulkstenis E, Subramanian GM, McHutchison JG,  
Efficacy and safety of albinterferon alfa-2B in combination with ribavirin in treatment naïve patients with chronic hepatitis C genotype 1  
*Hepatology*, 50:4, 333A, 2009
152. Lambert J, **Bain VG**, Thomson AB, Clandinin MT,  
Effectiveness of dietary intervention for liver post-transplant hyperlipidemia  
*Hepatology*, 50:4, 573A, 2009
153. Montano-Loza AJ, **Bain VG**, Ma M, Mason AL  
Incidence and risk factors associated with de novo autoimmune hepatitis after liver transplantation  
*Hepatology*, 50:4, 591A-592A, 2009
154. Benhamou Y, Nelson DR, Chuang W-L, Lawitz E, Flisiak R, Rasenack J, Kryczka W, Lee C-M, Rodriguez-Torres M, **Bain VG**, Schiff ER, Cho M, Janczewska-Kazek E, Peng C-Y, Pulkstenis E  
Efficacy and safety results of albinterferon alfa-2B in combination with ribavirin in treatment naïve subjects with chronic hepatitis C genotype 2 or 3  
*Hepatology*, 50:4, 1026A, 2009
155. Montano-Loza A, Mason A, Ma M, **Bain VG**, Tandon P  
Risk factors for recurrence of autoimmune hepatitis after liver transplantation  
*The Canadian Journal of Gastroenterology*, 23:A, 77A, 2009
156. Ye C, Meghana Saincher M, Tandon P, Meeberg G, Burak KW, **Bain VG**.  
Cardiac workup protocol for liver transplant candidates.  
*Hepatology*, 52:4, 842A, 2010
157. Zeuzem S, Pianko S, Foster GR, **Bain V**, Chuang WL, Sarin SK, Flisiak R, Lee CM, Shah SR,

- Andreone P, Piratvisuth T, Yin Y, Feutren G, Jacobson IM.  
Safety and efficacy of Albinterferon-Alfa-2B every four weeks plus ribavirin for treatment of chronic hepatitis C genotype 2/3.  
Hepatology, 52:4, 81A, 2010
158. Montano-Loza AJ, **Bain VG**, Mason AL  
Incidence and risk factors associated with de novo autoimmune hepatitis after liver Transplantation.  
Canadian Journal of Gastroenterology, 24:A, 72A, 2010
159. Peltekian K, **Bain V**, Lee S, Sherman M, Cooper C, Yoshida E, Marotta P, Krajden M, Usaty C, Balshaw R, Deschenes M.  
Is pre-treatment liver biopsy necessary in patients with chronic hepatitis C infections?  
Canadian Journal of Gastroenterology, 24:A, 157A, 2010
160. Meza-Junco J, Montano-Loza A, Prado C, Lieffers J, Baracos V, **Bain V**, Spratlin J, Sawyer M.  
Sarcopenia in Patients (pts) with Hepatocellular Carcinoma (HCC).  
Journal of Clinical Oncology, 29: Suppl Abstract e14570
161. Zeuzem S, Pianko S, Foster G, **Bain V**, Chuang W, Sarin S, Flisiak R, Lee C, Shah S, Andreone P, Piratvisuth T, Yin Y, Feutren G, Jacobson M.  
Safety and Efficacy of Albinterferon-alfa-2b Every four Weeks Plus Ribavirin for Treatment of Chronic Hepatitis C Genotype 2/3.  
AASLD, HCV Clinical Trials Abstract, 2010
162. Brown K, Pianko S, Sarin SK, Jacobson I, Piratvisuth T, Shah S, Andreone P, Lee CM, Gould M, **Bain V**, et al., 2010  
Decline in Pulmonary Physiology During Treatment of Chronic Hepatitis C with Long-Acting Interferon and Ribavirin.  
Journal of Respiratory Critical Care Medicine, 183, A3040, 2010
163. Montano-Loza A, **Bain V**, Ma M, Mason A.  
Incidence and Risk Factors Associated with De Novo Autoimmune Hepatitis After Liver Transplantation.  
Canadian Journal of Gastroenterology, 24:A, 72A-73A, 2010
164. Tandon P, Ney M, Irwin I, Ma M, Gramlich L, **Bain V**, Baracos V, Montano-Loza A, Myers R.  
Sarcopenia-An Objective Nutritional Assessment Tool that May Facilitate Prioritization of Liver Transplant Candidates.  
Hepatology, AASLD Abstracts, 54:4 (Suppl), 665A, 2011
165. Chandok N, Mason A, Adams P, Ma M, **Bain V**, Marotta P, Montano-Loza A.  
Assessment of the Optimal Dose of Azathioprine for Patients with Autoimmune Hepatitis.  
Hepatology, AASLD Abstracts, 54 :4 (Suppl), 912A, 2011

166. Asthana S, Burak KW, Bailey J, Myers R, Meeberg G, Mason A, **Bain V**, Kneteman N.  
Sirolimus-Based Immunosuppression is associated with Improved Sustained Virologic Response (SVR) to Antiviral Treatment for Patients with Recurrent Hepatitis C (HCV) Infection Post-Liver Transplant (LT)  
Hepatology, AASLD Abstracts, 54 :4 (Suppl), 451A, 2011
167. Montano-Loza A, Meza-Junco J, Prado C, Lieffers J, **Bain V**, Sawyer M.  
Sarcopenia Predicts Early Mortality in Patients with Cirrhosis  
Canadian Journal of Gastroenterology, 25:A (Suppl), 73A, 2011
168. Myers R, Faris P, Shaheen A, Aspinall A, Meeberg G, Tandon P, Kneteman N, **Bain V**, Burak K.  
Validation of the Five-Variable Model for End-Stage Liver Disease (5VMELD) for Predicting Mortality on the Liver Transplant Waiting List  
Canadian Journal of Gastroenterology, 25:A (Suppl), 74A, 2011
169. Cembrowski GS, Tran DV, Higgins TN, Blakney G, **Bain VG**.  
Evaluation of serial patient ALT and AST demonstrates 50% more biologic variability in AST : Another reason to stop ordering AST and ALT in tandem.  
AACC Annual Meeting, 12-A-1150-AACC, 2012
170. Meza-Junco J, Montano-Loza A, Prado C, Lieffers J, Baracos V, **Bain V**, Sawyer M.  
Sarcopenia in patients with hepatocellular carcinoma.  
Canadian Journal of Gastroenterology, 26 :(SupplA) :89A, 2012
171. Nelson DR, Lawitz E, **Bain V**, Gitlin N, Hawkins T, Marotta P, Workowski K, Flamm S, Pang PS, McHutchison JG, McNally J, Urbanek P, Yoshida EM.  
High SVR12 with 16 weeks of Tegobuvir and GS-9256 with Peginterferon-Alfa 2A and Ribavirin in treatment-naïve genotype 1 HCV patients.  
Journal of Hepatology, 56:(Suppl 2), S6-S7, 2012
172. Montano-Loza A, Purdy D, **Bain V**, Meza-Junco J, Ma M, Wong W, Owen R.  
Radioembolization with Yttrium-90 for Advanced Hepatocellular Carcinoma: A Canadian Experience.  
Journal of Hepatology, 58: S263, 2013
173. Montano-Loza A, Meza-Junco J, Prado C, Tandon P, **Bain V**, Ma M, Beaumont C, Esfandiari N, Sawyer M, Baracos V.  
New Cutoff Values for Sarcopenia for Predicting 6-month Mortality in Cirrhotic Patients.  
Journal of Hepatology, 58: S221, 2013
174. Alghanem M, Mason A, **Bain V**, Ma M, Kneteman N, Burak K, Montano-Loza A.  
Primary Sclerosing Cholangitis Recurs Earlier After Living Donor Liver Transplantation.  
Hepatology 58:(Suppl 4), 1014A, 2013

175. Selvarajah V, **Bain V**, Ma M, Bhanji R, Montano-Loza A.  
Management of Autoimmune Hepatitis in Canada: A National Survey.  
Canadian Journal of Gastroenterology, 27:(Suppl A), A180, 2013
176. Montano-Loza A, Meza-Junco J, Baracos V, Tandon P, **Bain V**, Ma M, Beaumont C, Esfandiari N, Sawyer M, Kneteman N,  
Muscle Wasting is Not Associated with Higher Mortality After Liver Transplantation.  
Canadian Journal of Gastroenterology, 27:(Suppl A), A35, 2013
177. Jayakumar S, Carbonneau M, Hotte N, Befus D, St. Laurent C, Owen R, McCarthy M, Madsen K, Bailey R, Ma M, **Bain V**, Rioux K, Tandon P.  
Probiotics do not Reduce Portal Pressure in Patients with Decompensated Cirrhosis.  
Canadian Journal of Gastroenterology, 27:(Suppl A), A31, 2013
178. D'Souza P, Montano-Loza A, Halloran B, Teshima C, Zepeda-Gomez S, **Bain V**, Sultanian R, Sandha G.  
A Novel Cholangioscopy-Assisted Clinical Subtyping System in Primary Sclerosing Cholangitis – The Edmonton Classification.  
Canadian Journal of Gastroenterology, 28:(Suppl A), A61, 2014
179. Montano-Loza A, **Bain V**, Alghanem M, Kneteman N, Burak K.  
Primary Sclerosing Cholangitis Recurs Earlier After Living Donor Transplant.  
Canadian Journal of Gastroenterology, 28:(Suppl A), A34, 2014
180. Tandon P, Abraldes J, Keough A, Bastiampillai R, Jayakumar S, Carbonneau M, Wong E, Kao D, **Bain V**, Ma M.  
The Effect of Antibiotics in Acute Variceal Hemorrhage: A Comparative Effectiveness Study.  
Canadian Journal of Gastroenterology, 28:(Suppl A), A58, 2014
181. Bhanji R, Ma M, **Bain V**, Montano-Loza A.  
Early Renal Dysfunction After Liver Transplantation is Associated with Reduced Graft and Patient Survival.  
Journal of Hepatology, 60:(Suppl A), 873, 2014
182. Flamm S, Gane E, DuFour J-F, Rustgi V, **Bain V**, Crawford D, et al.  
Safety of ABT-450/r/Ombitasvir + Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Patients  $\geq 65$  Years of Age: Results From Phase 2 and 3 Trials.  
Hepatology, 60:(Suppl A), 1157A, 2014
183. Feld J, Yoshida E, Ramji A, Tam E, **Bain V**, Ackad N, Baloukas J, Shulman N, Copper C.  
Safety and Efficacy of Ombitasvir-ABT-450/R and Dasabuvir +/- RVB in HCV Genotype 1-Infected Canadian Patients: Results from Phase 3 Trials.  
Canadian Journal of Gastroenterology and Hepatology, 29: (Suppl A), 144A, 2015
184. Bhanji R, Ma M, **Bain V**, Montano-Loza A.

Presence of Ascites and Hepatic Encephalopathy Pre-Liver Transplant are Associated with Negative Impact on Liver Transplant Survival.

Canadian Journal of Gastroenterology and Hepatology, 29: (Suppl A), 174A, 2015

**185.**Bhanji R, Ma M, **Bain V**, Montano-Loza A.

Early Renal Dysfunction After Liver Transplantation is Associated with Reduced Graft and Patient Survival.

Canadian Journal of Gastroenterology and Hepatology, 29: (Suppl A), 174A, 2015

**186.**Raubenheimer M, Abele JT, **Bain V**, Lalonde L, Coulden RA, Al Hulaimi N, et al.

Assessment of Vasodilatory Response to Dipyridamole in Patients with Liver Failure Undergoing <sup>82</sup>Rb-PET/CT Myocardial Perfusion Imaging Studies.

Radiological Study of North America, 2015